Virginia Kaklamani, MD, DSc, shares her excitement for an upcoming OncLive® "The TALK" program focusing on HER2-positive breast cancer updates from the SABCS 2021 Virtual Meeting.
Capivasertib/Fulvestrant Wins Approval in Japan for Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations
Revisit the OncLive On Air Episodes From February 2024
Ribociclib Plus Nonsteroidal Aromatase Inhibitor Extends iDFS in HR+/HER2– Early-Stage Breast Cancer
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
State of the Science Summit– Breast Cancer: Chaired by Rita Nanda, MD
Liquid Nitrogen–Based Cryoablation Leads to High RFS Rate in Low-Risk, Early-Stage Breast Cancer
MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors
First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC
Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC
Phase 2 IMscin002 Study Shows Patients With NSCLC Prefer Subcutaneous Atezolizumab